LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

MRK

115.6

+0.33%↑

LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

MRK

115.6

+0.33%↑

LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

MRK

115.6

+0.33%↑

LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

MRK

115.6

+0.33%↑

LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

MRK

115.6

+0.33%↑

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc
Search

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

497.91 -0.22

Strong Buy

Prijsupdate 17 jun 2026, 19:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

492.76

Max

507.15

Belangrijke statistieken

By Trading Economics

Inkomsten

-36M

-94M

Verkoop

-9.7M

311M

EPS

-1.38

Winstmarge

-30.318

Werknemers

915

EBITDA

-43M

-93M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+29.83% upside

Dividenden

By Acuity

Volgende Winsten

4 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.2B

11B

Vorige openingsprijs

498.13

Vorige sluitingsprijs

497.91

Nieuwssentiment

By Acuity

57%

43%

286 / 342 Rangschikking in Healthcare

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat